Cathie's Ark Logo
Fate Therapeutics Inc Logo

Combined Holdings of Fate Therapeutics (FATE) - Updated Daily

Gene TherapyGenomicsCAR-NK Gene TherapyStem CellsCRSPR Gene Editing
Morning Brew Icon
China's One Ocean Problem
Date
Direction
Shares
Fund Weight
Fund
January 10, 2023
SELL1.125k0.0001%ARKK
January 10, 2023
SELL827.0000.0002%ARKG
January 6, 2023
SELL5.860k0.0013%ARKG
January 6, 2023
SELL19.096k0.0014%ARKK
January 3, 2023
SELL2.293m1.2392%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
0%$531.52m
🏋️‍♀️Weight Rank Across All Funds🌏Country
216🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$46.82 - ARKG$78.47 - ARKK
0%
Description
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Website
www.fatetherapeutics.com

Research Notes and Commentary for FATE

January 29, 2021

Ark Trades and Storylines

Trading Floor
Reported excellent Phase 1 clinical trial results for it's experimental CAR-NK therapy on...